IDRA News 2.77 Idera Pharmaceuticals (IDRA)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Idera Pharmaceuticals (IDRA) 2.77 $IDRA

Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)
at The Street - Fri Apr 11, 9:10AM CDT
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Top Gainers Technical Data -- Research on BioScrip, E-House China Holdings, MagneGas, and Idera Pharma
PR Newswire - Wed Apr 09, 7:47AM CDT
On Tuesday, April 08, 2014, the US markets saw a positive sentiment, with the NASDAQ Composite closing at 4,112.99, up 0.81%, the Dow Jones Industrial Average ending the session at 16,256.14, up 0.06%, and the S&P 500 edging 0.38% higher to finish the trading session at 1,851.96. The session saw a positive impact from Consumer Discretionary, Energy and Utilities sectors along with a drag from Health Care, Industrials and Telecommunication Services sectors. A number of stocks saw large movements, including BioScrip Inc. (NASDAQ: BIOS), E-House China Holdings Ltd (NYSE: EJ), MagneGas Corp. (NASDAQ: MNGA) and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free technical research on BIOS, EJ, MNGA and IDRA can be downloaded upon signing up at:

Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic MYD88 L265P Mutation
Business Wire - Mon Apr 07, 3:05PM CDT
--- IMO-8400 in Phase 1/2 trial for Waldenstrom's macroglobulinemia -

Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Idera Pharmaceuticals, Inc. Bouncing on Phase 2 Success
Catherine Shaffer, The Motley Fool - Motley Fool - Tue Apr 01, 5:30PM CDT
Idera Pharmaceuticals ' stock market rollercoaster ride left it partially recovered from its 25% plunge just over a week ago upon FDA approval of a competing product developed by Celgene  . Idera's plaque psoriasis candidate, IMO-8400, gave good...

Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock
at The Street - Tue Apr 01, 8:48AM CDT
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Why MannKind, Momenta Pharmaceuticals, and Idera Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 31, 7:30PM CDT
Lately, the stock market has turned on every word from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from investors Monday. With Yellen offering a much more...

Idera Soars on Phase II Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:06PM CDT
Idera announced positive top-line data from a phase II study on IMO-8400.

Biggest Biotech Clinical Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 1:30PM CDT
Last week was full of great news for biotechs. Idera Pharmaceuticals   finally had some luck with a troubled program. Clovis Oncology   took a big step toward treating defined populations with unmet need with a drug and diagnostic combination....

Stock to Watch: Idera Pharmaceuticals Down 6.3% (IDRA)
Comtex SmarTrend(R) - Mon Mar 31, 11:41AM CDT
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 6.3% to $4.28 on 1.1x average daily volume. Thus far today, Idera Pharmaceuticals has traded 3.9 million shares, vs. average volume of 3.6 million shares per day. The stock has underperformed the Dow (-6.3% to the Dow's 0.9%) and underperformed the S&P 500 (-6.3% to the S&P's 0.9%) during today's trading.

BlackBerry Wins Preliminary Injunction against Ryan Seacrest's Typo Products; Red Hat Tumbles on Weak Guidance
ACCESSWIRE - Sun Mar 30, 11:17PM CDT
BlackBerry Limited (NASDAQ: BBRY) - For an in-depth report on BlackBerry Limited follow: www.BullTrends.com/stockquote/BBRY

This Week in Biotech: Biogen Idec Gets a Key Approval While Insmed Confuses Investors
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 29, 2:15PM CDT
With the  SPDR S&P Biotech Index  up  38% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...

Why Idera Pharmaceuticals, Bofi Holdings, and Eastman Kodak Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 4:15PM CDT
Following day after day of mixed economic data this week, the broad-based S&P 500 managed to muster up a solid gain on Friday after all data finally pointed in the correct direction. First off, the final Thomson Reuters/University of...

Why Idera Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 28, 12:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Idera Pharmaceuticals , a clinical-stage...

Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400
Business Wire - Fri Mar 28, 6:15AM CDT
--IMO-8400 also demonstrates clinical proof-of-concept in psoriasis

Idera Pharmaceuticals Down 9.2%, Shares Slide into the Red (IDRA)
Comtex SmarTrend(R) - Thu Mar 27, 11:41AM CDT
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 9.2% to $3.81 on 1.1x average daily volume. Idera Pharmaceuticals has traded 3.7 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has underperformed the Dow (-9.2% to the Dow's 0.0%) and underperformed the S&P 500 (-9.2% to the S&P's -0.2%) during today's trading.

Is Idera's Sell-Off Premature?
Catherine Shaffer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
Stock in Idera Pharmaceuticals tanked this week when Celgene announced that the FDA approved Otezla (apremilast) for psoriatic arthritis, a major competitor of Idera's Phase II candidate, IMO-8400. Both drugs face a crowded marketplace for...

Stock to Watch: Idera Pharmaceuticals Down 24.2% (IDRA)
Comtex SmarTrend(R) - Mon Mar 24, 10:11AM CDT
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 24.2% to $4.61 on 2.1x average daily volume. Thus far today, Idera Pharmaceuticals has traded 6.4 million shares, vs. average volume of 3.1 million shares per day. The stock has underperformed the Dow (-24.2% to the Dow's -0.2%) and underperformed the S&P 500 (-24.2% to the S&P's -0.6%) during today's trading.

Insider Buying Is On The Rise In These 4 Rallying Stocks
at The Street - Thu Mar 20, 5:16PM CDT
James Dennin, Kapitall: One way to evaluate small cap stocks is by looking for insider buying, when people on staff are buying [...]
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading